JP2010518085A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518085A5 JP2010518085A5 JP2009549116A JP2009549116A JP2010518085A5 JP 2010518085 A5 JP2010518085 A5 JP 2010518085A5 JP 2009549116 A JP2009549116 A JP 2009549116A JP 2009549116 A JP2009549116 A JP 2009549116A JP 2010518085 A5 JP2010518085 A5 JP 2010518085A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pyridinyl
- independently
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 methoxyphenyl Chemical group 0.000 claims description 277
- 150000001875 compounds Chemical class 0.000 claims description 239
- 125000000623 heterocyclic group Chemical group 0.000 claims description 103
- 125000001072 heteroaryl group Chemical group 0.000 claims description 102
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 97
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 91
- 229910052757 nitrogen Inorganic materials 0.000 claims description 90
- 125000003107 substituted aryl group Chemical group 0.000 claims description 90
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 85
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 82
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 82
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 80
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 79
- 125000001188 haloalkyl group Chemical group 0.000 claims description 56
- 125000001475 halogen functional group Chemical group 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 50
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 45
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 45
- 125000004432 carbon atom Chemical group C* 0.000 claims description 39
- 229910052717 sulfur Inorganic materials 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 36
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 34
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
- 125000004414 alkyl thio group Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 10
- 125000002883 imidazolyl group Chemical group 0.000 claims description 10
- 150000008512 pyrimidinediones Chemical class 0.000 claims description 10
- 125000000335 thiazolyl group Chemical group 0.000 claims description 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 9
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 9
- 125000005605 benzo group Chemical group 0.000 claims description 9
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 9
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims description 9
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 9
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 9
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 9
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 9
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 9
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 9
- 125000001041 indolyl group Chemical group 0.000 claims description 9
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 9
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 9
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 9
- 125000005888 tetrahydroindolyl group Chemical group 0.000 claims description 9
- 125000001544 thienyl group Chemical group 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 5
- 238000006731 degradation reaction Methods 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 4
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims description 4
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims description 4
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 239000013022 formulation composition Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 25
- 239000000651 prodrug Substances 0.000 description 19
- 229940002612 prodrug Drugs 0.000 description 19
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 6
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 0 CC(C)c1ccc(CC(*)(*)C2)c2c1 Chemical compound CC(C)c1ccc(CC(*)(*)C2)c2c1 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- DTXOCJGLLMAFBX-UHFFFAOYSA-N oxo-[[1-[2-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxy]ethoxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCCOCN1C=CC(=C[NH+]=O)C=C1 DTXOCJGLLMAFBX-UHFFFAOYSA-N 0.000 description 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 3
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000033014 Plasma cell tumor Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 210000001978 pro-t lymphocyte Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90022507P | 2007-02-08 | 2007-02-08 | |
| US60/900,225 | 2007-02-08 | ||
| US99370907P | 2007-09-13 | 2007-09-13 | |
| US60/993,709 | 2007-09-13 | ||
| PCT/US2008/001693 WO2008097640A2 (en) | 2007-02-08 | 2008-02-08 | Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518085A JP2010518085A (ja) | 2010-05-27 |
| JP2010518085A5 true JP2010518085A5 (enExample) | 2011-03-31 |
| JP5523839B2 JP5523839B2 (ja) | 2014-06-18 |
Family
ID=39624217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549116A Expired - Fee Related JP5523839B2 (ja) | 2007-02-08 | 2008-02-08 | 癌などの増殖障害の治療に有用なトリアゾール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8299107B2 (enExample) |
| EP (1) | EP2118077B1 (enExample) |
| JP (1) | JP5523839B2 (enExample) |
| KR (1) | KR101567608B1 (enExample) |
| CN (1) | CN101679319B (enExample) |
| AU (1) | AU2008214279B2 (enExample) |
| BR (1) | BRPI0807219A2 (enExample) |
| CA (1) | CA2677481C (enExample) |
| DK (1) | DK2118077T3 (enExample) |
| ES (1) | ES2533356T3 (enExample) |
| IL (1) | IL200241A0 (enExample) |
| MX (1) | MX2009008547A (enExample) |
| NZ (1) | NZ579403A (enExample) |
| PL (1) | PL2118077T3 (enExample) |
| TW (2) | TW201412310A (enExample) |
| WO (1) | WO2008097640A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52642B (sr) | 2004-11-18 | 2013-06-28 | Synta Pharmaceuticals Corp. | Jedinjenja triazola koja modulišu aktivnost hsp90 |
| WO2007021966A1 (en) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate hsp90 activity |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| EP2026797A2 (en) | 2006-05-25 | 2009-02-25 | Synta Pharmaceuticals Corporation | Method for treating non-hodgkin's lymphoma |
| TW200800260A (en) | 2006-05-25 | 2008-01-01 | Synta Pharmaceuticals Corp | Method for treating proliferative disorders associated with protooncogene products |
| DK2035396T3 (da) | 2006-05-25 | 2014-06-02 | Synta Pharmaceuticals Corp | Triazolforbindelser der modulerer hsp90-aktivitet |
| EP2032545A2 (en) * | 2006-05-25 | 2009-03-11 | Synta Pharmaceuticals Corporation | Compounds that modulate hsp90 activity and methods for identifying same |
| JP5441690B2 (ja) | 2006-05-25 | 2014-03-12 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| PL2118077T3 (pl) | 2007-02-08 | 2015-05-29 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność hsp90 |
| US8828665B2 (en) | 2007-02-16 | 2014-09-09 | Ark Diagnostics, Inc. | Compounds and methods for use in detecting gabapentin |
| US9156836B2 (en) * | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| WO2009158026A1 (en) * | 2008-06-27 | 2009-12-30 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate hsp90 activity |
| WO2010017479A1 (en) * | 2008-08-08 | 2010-02-11 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8106083B2 (en) | 2008-08-08 | 2012-01-31 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| EP2349335B1 (en) | 2008-10-24 | 2013-08-07 | ARK Diagnostics, Inc. | Levetiracetam immunoassays |
| EP2421833B1 (en) | 2009-04-21 | 2015-01-14 | Nerviano Medical Sciences S.r.l. | Resorcinol derivatives as hsp90 inhibitors |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| DK2655345T3 (en) * | 2010-12-20 | 2015-05-04 | Sigma Tau Res Switzerland Sa | Aryltriazole Compounds with Anti-tumor Effect |
| EP2729144A2 (en) | 2011-07-07 | 2014-05-14 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| AU2012332421A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| AU2013239663A1 (en) * | 2012-03-28 | 2014-10-09 | Synta Pharmaceuticals Corp. | Triazole derivatives as HSP90 inhibitors |
| US20150119395A1 (en) * | 2012-04-04 | 2015-04-30 | Synta Pharmaceuticals Corp. | Novel triazole compounds that modulate hsp90 activity |
| CA2888462A1 (en) * | 2012-10-19 | 2014-04-14 | Synta Pharmaceuticals Corp. | Treating polycystic kidney disease with hsp90 inhibitory compounds |
| US9970929B2 (en) | 2013-01-18 | 2018-05-15 | Ark Diagnostics, Inc. | Voriconazole immunoassays |
| EP2956444B1 (en) * | 2013-02-13 | 2018-05-30 | ARK Diagnostics, Inc. | Posaconazole immunoassays |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| US20170204089A1 (en) | 2014-08-04 | 2017-07-20 | Drexel University | Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same |
| US10568886B2 (en) | 2014-09-12 | 2020-02-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | Targeting Cyb5R3 |
| JP6760946B2 (ja) * | 2015-01-22 | 2020-09-23 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | Ｈｓｐ９０阻害剤としてのレゾルシノール誘導体 |
| MY193818A (en) | 2015-05-20 | 2022-10-27 | Amgen Inc | Triazole agonists of the apj receptor |
| CN106349233B (zh) * | 2015-07-15 | 2021-06-01 | 上海翰森生物医药科技有限公司 | 3,4-二苯基-4h-1,2,4-三唑衍生物及其制备方法和应用 |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| CN107540624B (zh) * | 2016-06-29 | 2020-06-16 | 广州市恒诺康医药科技有限公司 | 热休克蛋白抑制剂及其制备方法和应用 |
| WO2018026811A2 (en) * | 2016-08-01 | 2018-02-08 | Ohio State Innovation Foundation | Antifungal agents |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| US10689367B2 (en) | 2016-11-16 | 2020-06-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the APJ receptor |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| IL270091B2 (en) * | 2017-04-27 | 2025-08-01 | Codexis Inc | Ketoroductase polypeptides and polynucleotides |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
| CN109912584B (zh) * | 2019-03-22 | 2021-08-13 | 中国药科大学 | 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用 |
| CN114617888A (zh) * | 2020-12-14 | 2022-06-14 | 江苏豪森药业集团有限公司 | Egfr抑制剂治疗和预防眼部疾病或病况的医药用途 |
| CN117462551B (zh) * | 2023-12-27 | 2024-05-17 | 深圳国家感染性疾病临床医学研究中心 | 茚地那韦和/或其衍生物在制备抗结核药物中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4320801A1 (de) * | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
| US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| SE9603750D0 (sv) | 1996-10-14 | 1996-10-14 | Mydata Automation Ab | Plockhuvud för komponentmonteringsmaskin |
| AR022230A1 (es) * | 1999-01-12 | 2002-09-04 | Abbott Gmbh & Co Kg | Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion |
| ES2211420T3 (es) | 1999-07-21 | 2004-07-16 | F. Hoffmann-La Roche Ag | Derivados de triazol. |
| DE10109866A1 (de) * | 2001-03-01 | 2002-09-05 | Abbott Gmbh & Co Kg | Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie |
| AU2002358724A1 (en) * | 2001-12-21 | 2003-07-09 | Ciba Specialty Chemicals Holding Inc. | Use of metal complex compounds as oxidation catalysts |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| US20050075375A1 (en) * | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| EP1658273B1 (en) * | 2003-08-20 | 2007-01-03 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
| US20090074890A1 (en) * | 2003-11-10 | 2009-03-19 | Park Min K | Substituted Triazoles as Sodium Channel Blockers |
| WO2005063222A1 (ja) * | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
| WO2005082866A2 (en) * | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
| EP1730124A4 (en) * | 2004-03-26 | 2009-04-01 | Amphora Discovery Corp | Certain compounds based on triazole, compositions and applications thereof |
| DE102004051277A1 (de) * | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| RS52642B (sr) * | 2004-11-18 | 2013-06-28 | Synta Pharmaceuticals Corp. | Jedinjenja triazola koja modulišu aktivnost hsp90 |
| WO2006068199A1 (ja) * | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体 |
| JPWO2006080533A1 (ja) * | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | ３−アミノ−１，２，４−トリアゾール誘導体 |
| US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
| CN101160291B (zh) * | 2005-03-09 | 2012-09-05 | 日本化药株式会社 | 作为hsp90抑制剂的三唑衍生物 |
| JP2008137894A (ja) * | 2005-03-22 | 2008-06-19 | Nippon Kayaku Co Ltd | 新規なアセチレン誘導体 |
| US7662813B2 (en) | 2005-08-18 | 2010-02-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| WO2007088895A1 (ja) * | 2006-01-31 | 2007-08-09 | Mochida Pharmaceutical Co., Ltd. | ３－アリールアミノ－１,２,４－トリアゾール誘導体 |
| JP5441690B2 (ja) | 2006-05-25 | 2014-03-12 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| DK2035396T3 (da) * | 2006-05-25 | 2014-06-02 | Synta Pharmaceuticals Corp | Triazolforbindelser der modulerer hsp90-aktivitet |
| TW200806637A (en) | 2006-05-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Synthesis of triazole compounds that modulate HSP90 activity |
| WO2007139968A2 (en) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| BRPI0714407A2 (pt) * | 2006-07-14 | 2013-03-05 | Chemocentryx Inc | composto triazolil fenil benzeno-sulfonamida, composiÇço compreendendo o mesmo, usos do mesmo, mÉtodos de modulaÇço de funÇço de ccr2 e ccr9 |
| US7847577B2 (en) * | 2006-07-31 | 2010-12-07 | Sharp Kabushiki Kaisha | Active matrix substrate, display device, and active matrix substrate inspecting method |
| WO2008021364A2 (en) * | 2006-08-17 | 2008-02-21 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| KR20090045354A (ko) | 2006-08-21 | 2009-05-07 | 신타 파마슈티칼스 코프. | 증식성 장애를 치료하기 위한 화합물 |
| PL2118077T3 (pl) | 2007-02-08 | 2015-05-29 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność hsp90 |
| WO2009023211A1 (en) | 2007-08-13 | 2009-02-19 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| WO2010017479A1 (en) * | 2008-08-08 | 2010-02-11 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8106083B2 (en) | 2008-08-08 | 2012-01-31 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
-
2008
- 2008-02-08 PL PL08725339T patent/PL2118077T3/pl unknown
- 2008-02-08 BR BRPI0807219-1A patent/BRPI0807219A2/pt not_active IP Right Cessation
- 2008-02-08 ES ES08725339.9T patent/ES2533356T3/es active Active
- 2008-02-08 KR KR1020097018817A patent/KR101567608B1/ko not_active Expired - Fee Related
- 2008-02-08 WO PCT/US2008/001693 patent/WO2008097640A2/en not_active Ceased
- 2008-02-08 MX MX2009008547A patent/MX2009008547A/es active IP Right Grant
- 2008-02-08 US US12/526,491 patent/US8299107B2/en not_active Expired - Fee Related
- 2008-02-08 NZ NZ579403A patent/NZ579403A/en not_active IP Right Cessation
- 2008-02-08 EP EP08725339.9A patent/EP2118077B1/en not_active Not-in-force
- 2008-02-08 CA CA2677481A patent/CA2677481C/en not_active Expired - Fee Related
- 2008-02-08 JP JP2009549116A patent/JP5523839B2/ja not_active Expired - Fee Related
- 2008-02-08 CN CN200880010623.XA patent/CN101679319B/zh not_active Expired - Fee Related
- 2008-02-08 DK DK08725339T patent/DK2118077T3/en active
- 2008-02-08 AU AU2008214279A patent/AU2008214279B2/en not_active Ceased
- 2008-02-12 TW TW102138982A patent/TW201412310A/zh unknown
- 2008-02-12 TW TW097104944A patent/TWI417093B/zh not_active IP Right Cessation
-
2009
- 2009-08-05 IL IL200241A patent/IL200241A0/en unknown
-
2012
- 2012-10-26 US US13/662,218 patent/US8748424B2/en not_active Expired - Fee Related
-
2014
- 2014-06-03 US US14/294,717 patent/US20140288301A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518085A5 (enExample) | ||
| JP2010536753A5 (enExample) | ||
| JP2010522750A5 (enExample) | ||
| CA2682665A1 (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors | |
| JP2009538320A5 (enExample) | ||
| JP2009538321A5 (enExample) | ||
| JP2009538322A5 (enExample) | ||
| ES2806135T3 (es) | Nuevos inhibidores de bromodominios bicíclicos | |
| DK2938598T3 (en) | Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1 | |
| CN113316574A (zh) | Shp2抑制剂及其应用 | |
| CN103764655B (zh) | 作为alk5和／或alk4抑制剂的经2‑吡啶基取代的咪唑 | |
| CA3034705A1 (en) | Inhibitors of cellular metabolic processes | |
| JP2023015338A (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| EA013434B1 (ru) | Имидазохинолины в качестве ингибиторов липидкиназы | |
| AU2019243289A1 (en) | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | |
| US11472788B2 (en) | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | |
| HUP0500163A2 (hu) | Pirazolo [5,1-b] kinazolin származékok és ezeket tartalmazó gyógyszerkészítmények mint az IMPDH enzim inhibitorai | |
| CA2671982A1 (en) | Methods of using mek inhibitors | |
| CA2918938A1 (en) | Substituted aminopyrimidine compounds and methods of use | |
| WO2017214339A4 (en) | Anti-b7-h3 antibodies and antibody drug conjugates | |
| JP2013508373A (ja) | Ｔｏｌｌ様受容体の調節因子 | |
| HRP20130095T1 (hr) | Spojevi triazola koji moduliraju aktivnost hsp90 | |
| JP2018536681A (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| RU2018114289A (ru) | Бициклические соединения в качестве ингибиторов аутотаксина (atx) | |
| Hu et al. | Imidazole scaffold based compounds in the development of therapeutic drugs |